Momo Medical vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI bed sensor system for nursing homes preventing pressure ulcers with 30% care efficiency improvement; $8.89M Series A from PGGM serving 250 facilities across Netherlands, Germany, and US.
About
Momo Medical is a medical technology company developing AI-powered bed sensor systems for nursing homes that monitor patient position and mobility — detecting when nursing home residents have been in the same position for too long (increasing pressure ulcer risk) and alerting care staff with optimal repositioning recommendations, making nursing care more proactive and efficient. Founded in the Netherlands and backed by Y Combinator, Momo Medical raised $9 million total including an $8.89 million Series A led by PGGM (a Dutch pension fund manager) in August 2024.\n\nMomo Medical's under-mattress sensor pad continuously monitors patient position without requiring wearables or cameras, providing pressure distribution data and movement detection that feeds into an AI system. The system learns each patient's typical movement patterns and identifies deviations that may indicate clinical concerns. For nursing staff, Momo provides a dashboard showing all patients' positioning status, flagging who needs repositioning, and eliminating the need for manual turn schedules (which are often missed during busy shifts). The company claims a 30% improvement in nursing staff effectiveness through reduction of unnecessary rounds and better-timed interventions.\n\nIn 2025, Momo Medical serves 250 nursing home locations across the Netherlands, Germany, Canada, and the United States, with 246% revenue growth in 2023 demonstrating strong market pull. The company competes in the elder care monitoring space with EarlySense (bed sensor for acute care), Oxevision (optical monitoring), and various wearable patient monitoring solutions for nursing home safety and care efficiency. Pressure ulcers are one of the most prevalent and preventable nursing home complications, costing healthcare systems billions annually. The PGGM backing is strategically significant — PGGM manages pension funds for Dutch healthcare workers, creating a natural distribution channel through the Dutch healthcare system. The 2025 strategy focuses on scaling across more European nursing home networks and growing the North American presence.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.